Drug Profile
Tyzivumab - Tychan/WuXi Biologics
Alternative Names: TY-008; ZAb-FLEP; Zika mAbLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Tychan
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Zika-virus-infection in Singapore (IV, Infusion)
- 31 Mar 2022 Phase-I development is ongoing in Zika-virus-infection in Singapore (IV, Infusion) (Tychan pipeline, March 2022)
- 24 Mar 2022 Tychan in collaboration with Singapore Clinical Research Institute withdraws a phase-I clinical trial in Zika virus infection in Singapore (IV), prior to enrollment initiation, due to lack of Zika virus infection patients (NCT03776695)